CN1919192A - Curcumenol self-emulsifying capsule and preparation method thereof - Google Patents
Curcumenol self-emulsifying capsule and preparation method thereof Download PDFInfo
- Publication number
- CN1919192A CN1919192A CNA200610030237XA CN200610030237A CN1919192A CN 1919192 A CN1919192 A CN 1919192A CN A200610030237X A CNA200610030237X A CN A200610030237XA CN 200610030237 A CN200610030237 A CN 200610030237A CN 1919192 A CN1919192 A CN 1919192A
- Authority
- CN
- China
- Prior art keywords
- curcumenol
- emulsifying
- oil
- self
- polyoxyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Disclosed is a curcumenol self-emulsifying capsule preparation and its preparing process, wherein the capsule preparation is prepared from curcumenol, oil and emulsifying agent through dissolving curcumenol into oil through agitating or ultrasonic sound at 25-85 deg C, charging emulsifying agent, stirring homogeneously and encapsulating. The preparation can be made into soft capsules or hard capsules having better stability, higher biological availability, easier body absorption, improved curative effect and easier administration.
Description
Technical field
The present invention relates to medical technical field, specifically relate to a kind ofly have antitumor, antibiotic, antiviral, mutation and Curcumenol self-emulsifying capsule preparation of therapeutical effect and preparation method thereof such as protect the liver.
Background technology
Curcumenol (Curcumol) has another name called Rhizoma Curcumae Longae ring alcohol difficult to understand, curcumol, belongs to terpenoid, is the important component in the Rhizoma Curcumae volatile oil.Molecular formula is C
15H
24O
2, molecular weight 236.34.From the seventies, be applied to the treatment of cervical cancer, and obtain certain curative effect.In recent years. pharmacy worker has carried out extensive studies to curcumenol and has shown, pharmacological actions such as curcumenol has antitumor, antiearly pregnancy, antiviral, mutation, protects the liver, blood circulation promoting and blood stasis dispelling, wherein curcumenol has attracted the sight of numerous researcheres in the effect of anti-tumor aspect.
It is reported (Liu Zhimin, Xu Lichun, Chinese basic unit medicine, 2005,12 (7): 938.), curcumenol is to murine sarcoma S37, and the suppression ratio of 75mg/kg dosage is 53.47%～61.96%; During 75mg/kg dosage, be 45.7%～77.13% to mouse cervical cancer U14 suppression ratio; To mice ehrlich carcinoma (EAC), during 75mg/kg dosage, its suppression ratio is 65.8%～78.9%.Further experiment shows that the RNA that curcumenol significantly suppresses Hela, Mcf7, MM231 synthesizes, to the growth unrestraint effect of normal person's mammary glandular cell Mcf10a, Mcf12a.Studies show that according to Yangzhou University's medical college combination of Chinese and Western medicine institute, with curcumenol gastric cancer SGC-7901 cell, hepatocarcinoma HePG cell are carried out in vitro study, find curcumenol to gastric cancer SGC-7901, hepatocarcinoma HePG cell 50 μ g/ml suppression ratio can reach more than 60%.Curcumenol does not have influence to normal cell growth, and prolonged application is harmless to main organs.The curcumenol extract is given rat, and Canis familiaris L. was irritated stomach 7 days, and the weight of animals, hemogram, electrocardio, hepatic and renal function and organize microscopy all not have obvious influence this shows that curcumenol has characteristics of high efficiency and low toxicity as antitumor drug.
In recent years, antibiotic and the antiviral effect of curcumenol arouses attention just gradually, studies show that (Deng Rong, Chen Jimin etc., Liaoning medicine and clinical, 2001,4 (1): 39.), curcumenol can suppress the growth of staphylococcus aureus, Hemolytic streptococcus, escherichia coli, Bacillus typhi etc. in vitro.(RSW) has direct repression to respiratory syncytial virus, to influenza virus A
1Type and A3 type have direct deactivation.In addition, still can be to other virus as rheumatism virus, chickenpox virus directly acts on, simultaneously may be to parainfluenza virus, paramyxovirus, Coxsackie virus etc. also has inhibitory action.
This shows that curcumenol has broad prospects aspect clinical practice, but because it is water-soluble hardly, dissolubility in water only is 0.3% (Deng Rong, Chen Jimin, Yao Chongshun etc., Liaoning medicine and clinical, 2001,4 (1): 37.), belong to the solid drugs that is insoluble in water, so make peroral dosage forms such as conventional tablet, drop pill, solid gum wafer, can cause bioavailability low, absorb incomplete problem.In order to improve the curcumenol oral administration biaavailability, seeking a kind of appropriate formulation is a research work highly significant.
Summary of the invention
The invention provides a kind of Curcumenol self-emulsifying capsule preparation and preparation method thereof.
Curcumenol self-emulsifying capsule preparation of the present invention is made up of curcumenol, oil and emulsifying agent.It has advantages such as drug loading is big, bioavailability is high, preparation technology is simple, taking convenience.
Curcumenol self-emulsifying capsule preparation of the present invention is the precursor that its Emulsion forms, the principle of its effect is based on following known technology theory: self-emulsifying drug delivery system (Self-EmulsifyingDrug Delivery System, SEDDS) be the precursor that Emulsion forms, for comprising medicine, oil, the solid of surfactant and cosurfactant or homogeneous, transparent liquid dosage form, the basic feature of this system is the spontaneous formation oil in water emulsion of energy in gastrointestinal tract or under the situation of ambient temperature (being often referred to 37 ℃ of body temperature) and gentle agitation, thereby rely on tiny oil droplet specific surface area increase and significantly improve the dissolution of water-insoluble drug in gastrointestinal tract, increase bioavailability of medicament greatly, the Emulsion of Xing Chenging also can reduce medicine simultaneously stimulates gastrointestinal.
Curcumenol self-emulsifying capsule preparation of the present invention is made up of curcumenol, oil and emulsifying agent.The gram of its component/gram % content is curcumenol 0.1～20%, oil 40～99.9%, emulsifying agent 0～40%.
Its medium oil includes but not limited to soybean oil, fish oil, Semen Lini oil, Oleum Helianthi, Radix Oenotherae erythrosepalae oil, Oleum Hippophae, safflower oil, Oleum sesami, Semen Maydis oil, olive oil, hot tricaprin, sad monoglyceride, Sunfat GDC-S, Trivent OCG, capric acid monoglyceride, capric acid diglyceride, tricaprin, hot capric acid monoglyceride or hot capric acid diglyceride etc., selects one or more mixture for use.
Emulsifying agent comprises but is not limited to polyoxyethylene castor oil condensation substance, polyoxyethylene hydrogenated Oleum Ricini condensation substance, polysorbate, lecithin, poloxamer 188, Xin Pugao effect solubilizing agent series etc., is selected from one or more mixture.Wherein the polyoxyethylene castor oil condensation substance is preferably selected from polyoxyethylene (10～100) Oleum Ricini, and the best is polyoxyethylene (40) Oleum Ricini, polyoxyethylene (60) Oleum Ricini, in one or more mixture; The polyoxyethylene hydrogenated Oleum Ricini condensation substance is preferably selected from polyoxyethylene (10～100) castor oil hydrogenated, and the best is polyoxyethylene (40) castor oil hydrogenated, polyoxyethylene (60) castor oil hydrogenated, in one or more mixture; Polysorbate is preferably selected from polysorbate60, polysorbate65, polysorbate80, polysorbate85, and the best is polysorbate80, polysorbate85, in one or more mixture; Suffering regular senior middle school imitates solubilizing agent series (by the production of Xin Pu company) and includes but not limited to that Xin Pugao is imitated solubilizing agent SF-410, Xin Pugao effect solubilizing agent SF-400, Xin Pugao effect solubilizing agent HD-608, Xin Pugao are imitated solubilizing agent HD-508, Xin Pugao effect solubilizing agent TCS-100P, Xin Pugao and imitated solubilizing agent SF-600 etc., selects one or more mixture for use.
The preparation method of Curcumenol self-emulsifying capsule preparation of the present invention, may further comprise the steps: press formula ratio with curcumenol under temperature 25-85 ℃, by stirring or ultrasonicly fully being dissolved in it in oil, add emulsifying agent again, stir or ultrasonicly make it become homogeneous, transparent solution, then it is potted in the capsule, promptly gets the Curcumenol self-emulsifying capsule preparation.
Curcumenol self-emulsifying capsule preparation of the present invention contains active constituents of medicine curcumenol 2-300mg in every seed lac wafer.
Curcumenol self-emulsifying capsule preparation of the present invention can be hard capsule preparation or soft capsule preparation.Capsule is the commercially available prod, usually can be by arabic gum, and tragcanth, carrageenan, gelatin, methylcellulose are that material is made, the preferred gelatine capsule of the present invention.
Curcumenol self-emulsifying capsule preparation provided by the invention has overcome the problem of aspects such as the fat-soluble medicine bioavailability is low, drug loading is low, is a kind of oral drugs very easily.Said preparation will become the medicine of aspects such as a kind of novel effective antitumor medicine, antibiotic, antiviral and tumor aid treatment.Also lay a good foundation for the experimentation of curcumenol and clinical practice.
The superiority of Curcumenol self-emulsifying capsule preparation that the present invention is prepared and preparation method thereof shows following several respects:
1, Curcumenol self-emulsifying capsule preparation of the present invention, problems such as the principal agent curcumenol is separated out, structural change, degraded were not found in long-term preservation through 2 years, and stability is preferably arranged.
2, selected oil has good mobility, principal agent is had bigger dissolubility and very easily emulsified characteristic in preparation of the present invention, easy in vivo degraded and absorbed.
3, selected emulsifying agent is a safety in preparation of the present invention, nontoxic, non-irritating non-ionic surface active agent, and emulsifiability is good, finds that by external emulsifying experiment back its emulsifying particle diameter is less, helps gastrointestinal absorption, the bioavailability height.
4, Curcumenol self-emulsifying capsule preparation of the present invention is bigger because of medicine dissolubility in oil, need not use cosurfactant, not only save cost, also avoid using the derivant such as long-chain alcohol, ethylene glycol, propylene glycol, polyglycereol of cosurfactant and made the softening or dissolving of capsule material, caused drug extravasation.
5, Curcumenol self-emulsifying capsule preparation of the present invention is the precursor that its Emulsion forms, and can avoid that Emulsion layering, flocculation, phase inversion often occur in using, phenomenon such as break and become sour.
6, Curcumenol self-emulsifying capsule preparation of the present invention can be more fast, equably with drug delivery to absorption site, can form the little emulsion droplet that includes dissolved substance when contacting with gastro-intestinal Fluid, fine emulsion droplet has bigger interfacial area and medicine can maintain molecularity in gastrointestinal tract, can pass gastrointestinal tract mucously better, effectively increase bioavailability of medicament.Medicine not only can absorb from blood capillary under the mucosa after simultaneously preparation was converted into Emulsion, but and under the through mucous membrane lymphatic vessel absorb, can further improve drug absorption, improve curative effect.
7, Curcumenol self-emulsifying capsule preparation of the present invention usually Emulsion preparation is simple, and production process do not have dust, pollutes fewly, helps environmental protection.
8, Curcumenol self-emulsifying capsule preparation of the present invention, the preferential gelatine capsule of capsule does not have any harm to health, and production cost is low, and the automaticity height quantitatively accurately, is easy to disintegrate, stripping, and absorption of human body is fast.
The specific embodiment
Embodiment 1
Take by weighing decanoyl/octanoyl glycerides 420g, add curcumenol 185g, under 25 ℃ of temperature, it is fully dissolved by ultrasonic, add polyoxyethylene (40) Oleum Ricini 395g then, under 25 ℃ of temperature, stir and make it become homogeneous, transparent solution, adopt pressing, being equipped with into specification with rotation Zhanang mechanism automatically is every soft capsule that contains content 1.5g, promptly every to contain curcumenol be 277.5mg.Measure through Zetasizer Nano S type nano particle size instrument, the mean diameter of self emulsifying is 60nm under the situation of this self-emulsifying soft capsule preparation gentle agitation in external 37 ℃ water, and distribution is between 50nm～80nm.
Embodiment 2
Take by weighing soybean oil 540g, mix homogeneously, add curcumenol 150g, under 45 ℃ of conditions, it is fully dissolved, add Xin Pugao then and imitate solubilizing agent TCS-100P 263g, polyoxyethylene (60) castor oil hydrogenated 47g, under 50 ℃ of conditions, stir and make it become homogeneous, transparent solution by ultrasonic, fill, seal, be prepared into every hard capsule that contains content 1.2g, promptly every to contain curcumenol be 180mg.Measure through Zetasizer Nano S type nano particle size instrument, the mean diameter of self emulsifying is 80nm under the situation of this self emulsifying hard capsule preparation gentle agitation in external 37 ℃ water, and distribution is between 70nm～100nm.
Embodiment 3
Take by weighing safflower oil 377g, Oleum sesami 98g, Semen Maydis oil 73g, Semen Lini oil 70g, Oleum Hippophae 140g, mix homogeneously, add curcumenol 100g, under 75 ℃ of conditions, it is fully dissolved by stirring, add lecithin 25g, polysorbate65 42g, Xin Pugao effect solubilizing agent SF-410 57g, Xin Pugao effect solubilizing agent SF-400 18g then, under 75 ℃ of conditions, stir and make it become homogeneous, transparent solution, adopt pressing, being equipped with into specification with automatic rotation Zhanang mechanism is every soft capsule that contains content 1g, promptly every to contain curcumenol be 100mg.Measure through ZetasizerNano S type nano particle size instrument, the mean diameter of self emulsifying is 200nm under the situation of this self-emulsifying soft capsule preparation gentle agitation in external 37 ℃ water, and distribution is between 190nm～220nm.
Embodiment 4
Take by weighing tricaprin 220g, hot capric acid monoglyceride 123g, hot capric acid diglyceride 127g, Trivent OCG 250g,, mix homogeneously, add curcumenol 80g, under 80 ℃ of conditions, it is fully dissolved by stirring, add polysorbate80 88g, Xin Pugao then and imitate solubilizing agent HD-608 85g, Xin Pugao effect solubilizing agent HD-508 27g, under 75 ℃ of conditions, stir and make it become homogeneous, transparent solution, adopt pressing, being equipped with into specification with automatic rotation Zhanang mechanism is every soft capsule that contains content 0.8g, promptly every to contain curcumenol be 64mg.Measure through Zetasizer Nano S type nano particle size instrument, the mean diameter of self emulsifying is 270nm under the situation of this self-emulsifying soft capsule preparation gentle agitation in external 37 ℃ water, and distribution is between 250nm～350nm.
Embodiment 5
Take by weighing olive oil 194g, capric acid diglyceride 296g, Oleum Helianthi 130g, Radix Oenotherae erythrosepalae oil 120g, fish oil 160g, mix homogeneously, add curcumenol 30g, under 60 ℃ of conditions, it is fully dissolved by stirring, add polyoxyethylene (40) Oleum Ricini 8g then, stir under 65 ℃ of conditions and make it become homogeneous, transparent solution, fill is sealed, being prepared into specification is every soft capsule that contains content 0.8g, promptly every to contain curcumenol be 64mg.Measure through Zetasizer Nano S type nano particle size instrument, the mean diameter of self emulsifying is 350nm under the situation of this self emulsifying hard capsule preparation gentle agitation in external 37 ℃ water, and distribution is between 250nm～600nm.
Embodiment 6
Take by weighing sad monoglyceride 437g, capric acid monoglyceride 92g, Sunfat GDC-S 463g, mix homogeneously, add curcumenol 8g, under 60 ℃ of conditions, it is fully dissolved by stirring, stir under 65 ℃ of conditions and make it become homogeneous, transparent solution, fill is sealed, being prepared into specification is every hard capsule that contains content 0.3g, promptly every to contain curcumenol be 2.4mg.Measure through ZetasizerNano S type nano particle size instrument, the mean diameter of self emulsifying is 450nm under the situation of this self emulsifying hard capsule preparation gentle agitation in external 37 ℃ water, and distribution is between 250nm～600nm.
Claims (8)
1. a Curcumenol self-emulsifying capsule preparation is characterized in that being made up of curcumenol, oil and emulsifying agent, and the gram of its component/gram % content is: curcumenol 0.1～20%, oil 40～99.9%, emulsifying agent 0～40%.
2. Curcumenol self-emulsifying capsule preparation according to claim 1 is characterized in that containing in every seed lac wafer active constituents of medicine curcumenol 2～300mg.
3. Curcumenol self-emulsifying capsule preparation according to claim 1 is characterized in that described capsule preparations is hard capsule preparation or soft capsule preparation.
4. Curcumenol self-emulsifying capsule preparation according to claim 1 is characterized in that described component oil is selected from one or more mixture in soybean oil, fish oil, Semen Lini oil, Oleum Helianthi, Radix Oenotherae erythrosepalae oil, Oleum Hippophae, safflower oil, Oleum sesami, Semen Maydis oil, olive oil, hot tricaprin, sad monoglyceride, Sunfat GDC-S, Trivent OCG, capric acid monoglyceride, capric acid diglyceride, tricaprin, hot capric acid monoglyceride or the hot capric acid diglyceride.
5. Curcumenol self-emulsifying capsule preparation according to claim 1 is characterized in that described component emulsifying agent is selected from polyoxyethylene castor oil condensation substance, polyoxyethylene hydrogenated Oleum Ricini condensation substance, polysorbate, lecithin, poloxamer 188 or Xin Pugao and imitates in the solubilizing agent series one or more mixture.
6. Curcumenol self-emulsifying capsule preparation according to claim 5 is characterized in that the condensation substance of polyoxyethylene castor oil described in the emulsifying agent is selected from polyoxyethylene (10～100) Oleum Ricini one or more mixture; Described polyoxyethylene hydrogenated Oleum Ricini condensation substance is selected from polyoxyethylene (10～100) castor oil hydrogenated one or more mixture; Described polysorbate is selected from one or more the mixture in polysorbate60, polysorbate65, polysorbate80 or the polysorbate85; Described hot regular senior middle school imitates solubilizing agent series and is selected from Xin Pugao and imitates solubilizing agent SF-410, Xin Pugao and imitate solubilizing agent SF-400, Xin Pugao and imitate solubilizing agent HD-608, Xin Pugao and imitate solubilizing agent HD-508, Xin Pugao and imitate solubilizing agent TCS-100P or Xin Pugao and imitate among the solubilizing agent SF-600 one or more mixture.
7. Curcumenol self-emulsifying capsule preparation according to claim 5 is characterized in that the condensation substance of polyoxyethylene castor oil described in the emulsifying agent is selected from a kind of or its mixture in polyoxyethylene (40) Oleum Ricini or polyoxyethylene (60) Oleum Ricini; Described polyoxyethylene hydrogenated Oleum Ricini condensation substance is selected from a kind of or its mixture in polyoxyethylene (40) castor oil hydrogenated or polyoxyethylene (60) castor oil hydrogenated; Described polysorbate is selected from a kind of or its mixture in polysorbate80 or the polysorbate85.
8. the preparation method of Curcumenol self-emulsifying capsule preparation according to claim 1 be by formula ratio with curcumenol under temperature 25-85 ℃, by stir or ultrasonic dissolution in oil, add emulsifying agent again, stir or the ultrasonic solution that becomes, be potted in then in the capsule, promptly get the Curcumenol self-emulsifying capsule preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200610030237XA CN1919192A (en) | 2006-08-21 | 2006-08-21 | Curcumenol self-emulsifying capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200610030237XA CN1919192A (en) | 2006-08-21 | 2006-08-21 | Curcumenol self-emulsifying capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1919192A true CN1919192A (en) | 2007-02-28 |
Family
ID=37777133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200610030237XA Pending CN1919192A (en) | 2006-08-21 | 2006-08-21 | Curcumenol self-emulsifying capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1919192A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055528A (en) * | 2015-08-10 | 2015-11-18 | 山东罗欣药业集团股份有限公司 | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof |
| CN105287428A (en) * | 2015-11-20 | 2016-02-03 | 河北科技大学 | Preparation method of brucea javanica oil self-emulsifying liquid hard capsule |
| CN110403914A (en) * | 2019-06-13 | 2019-11-05 | 兰溪市立顺生物有限公司 | Carboxylic acid for children's early stage application |
| CN110711190A (en) * | 2019-09-20 | 2020-01-21 | 广西科学院 | Terpenoid inhibitor for resisting fish diseases and preparation method and application thereof |
-
2006
- 2006-08-21 CN CNA200610030237XA patent/CN1919192A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055528A (en) * | 2015-08-10 | 2015-11-18 | 山东罗欣药业集团股份有限公司 | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof |
| CN105055528B (en) * | 2015-08-10 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of Chinese medicine composition self-emulsifying soft capsule and preparation method thereof for treating flu |
| CN105287428A (en) * | 2015-11-20 | 2016-02-03 | 河北科技大学 | Preparation method of brucea javanica oil self-emulsifying liquid hard capsule |
| CN110403914A (en) * | 2019-06-13 | 2019-11-05 | 兰溪市立顺生物有限公司 | Carboxylic acid for children's early stage application |
| CN110711190A (en) * | 2019-09-20 | 2020-01-21 | 广西科学院 | Terpenoid inhibitor for resisting fish diseases and preparation method and application thereof |
| CN110711190B (en) * | 2019-09-20 | 2023-08-25 | 广西科学院 | Terpenoid inhibitor for resisting fish diseases and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Self emulsifying drug delivery system (SEDDS): Future aspects | |
| CN1196477C (en) | Pharmaceutical compsn. for oral delivery | |
| WO2020147416A1 (en) | Terpene pharmaceutical composition self-emulsifying oral preparation, preparation method therefor and use thereof | |
| EP2062571B1 (en) | Self-emulsifying pharmaceutical composition with enhanced bioavailability | |
| US20040147578A1 (en) | Use of lipoaminoacids as absorption promoters in a pharmaceutical composition | |
| Kermanizadeh et al. | Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape | |
| US20210393780A1 (en) | Thermosensitive hydrogel for cancer therapeutics and methods of preparation thereof | |
| CN1857239A (en) | Coenzyme Q10 injection emulsion and its preparing process | |
| CN101057829A (en) | Supersaturated cationic self-emulsified drug delivery system and its preparation method | |
| CN1919192A (en) | Curcumenol self-emulsifying capsule and preparation method thereof | |
| WO2011103806A1 (en) | Oral microemulsion of elemene | |
| CN1706371B (en) | Efficient sword-like iris seed preparation and its preparation process | |
| CN105919949B (en) | A kind of flurbiprofen axetil freeze-drying breast of stabilization and preparation method thereof | |
| CN105688220A (en) | Pharmaceutical composition containing butylphthalide and novel solubilizer | |
| EP1249231B1 (en) | Pharmaceutical formulations comprising anti-inflammatory compounds and use thereof | |
| CN103505414B (en) | Butylphthalide nasal drop and preparation method thereof | |
| CN101147727A (en) | Curcumol submicron emulsion and preparation method and preparation thereof | |
| RU2582278C2 (en) | Transdermal agent for treating and preventing joint and soft tissue diseases, method for production thereof and combined transdermal preparation for treating and preventing joint and soft tissue diseases | |
| CN106511272A (en) | Anti-hepatitis baicalin O/W type oral nano-emulsion and preparation method thereof | |
| CN1264509C (en) | Precursor liposome preparation containing silybum marianum extract and its preparing process | |
| CN1810240A (en) | Prepn process and use of total andrographolide emulsion | |
| Zhang et al. | Liquid Crystalline Phases for Enhancement of Oral Bioavailability | |
| POJARANİ et al. | Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications | |
| CN1686156A (en) | Clamycin structurization emulsion composition | |
| WO2019140516A1 (en) | Oral formulations of metronidazole and methods of treating an infection using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |